Read that line carefully
Studies have shown that DSIP can pass the blood brain barrier (BBB) in rats, mice, dogs, and humans, making it a potential option for targeting neurological disorders, aforementioned mood disorders, and sleep disorders [11]

Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic injection 0.5 mg + basal insulin MET 10.7% with Ozempic injection 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified

Its your time to thrive!
Fang B, Chen Y, Zhang R, Wang L, Correa A, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng Q, Fujimoto J, Jensen V, Antonoff M, Hofseter W, Huynh T, Mehran R, Pisimissis G, Rice D, Sepesi B, Vaporciyan AA, Walsh G, Roth J, Swisher SG , Heymach J
Is BPC-157 Included in Drug Tests